In an adult with heart failure with reduced ejection fraction, type 2 diabetes, and chronic kidney disease (eGFR >25 mL/min/1.73 m²) and baseline serum potassium ≤4.8 mmol/L, how should finerenone be initiated, dosed, monitored, and what are its contraindications?

Finerenone in Heart Failure with Reduced Ejection Fraction

In adults with HFrEF, type 2 diabetes, and CKD, finerenone is NOT recommended as a primary therapy—prioritize SGLT2 inhibitors first, which have stronger evidence for mortality reduction in this population. 1

Current Guideline Position

The 2025 BMJ living guideline explicitly suggests against using finerenone in patients with CKD at moderate cardiovascular and kidney risk, citing "little or no benefit" on major outcomes, risk of severe hyperkalemia, and limited clinical experience compared to established therapies 1. This recommendation applies even when diabetes is present.

The guideline strongly recommends SGLT2 inhibitors or GLP-1 receptor agonists for patients at higher risk with established CVD or CKD, based on high-certainty evidence for survival benefits 1. For HFrEF specifically, SGLT2 inhibitors have demonstrated mortality reduction with high-certainty evidence 1.

Evidence Context for HFrEF

The major finerenone trials (FIDELIO-DKD, FIGARO-DKD) focused on diabetic kidney disease and showed 22% reduction in HF hospitalizations 2. However, the landmark FINEARTS-HF trial specifically enrolled patients with LVEF ≥40% (HFmrEF/HFpEF), not HFrEF 3, 4. This is a critical distinction—the robust evidence for finerenone reducing worsening HF events applies to preserved or mildly reduced EF, not reduced EF.

Clinical Algorithm for Your Patient

Step 1: Optimize Proven HFrEF Therapies First

• SGLT2 inhibitor (dapagliflozin or empagliflozin) - mortality benefit with high-certainty evidence 1
• ACE inhibitor/ARB or ARNI
• Beta-blocker
• Consider spironolactone/eplerenone if LVEF ≤35% and symptomatic despite above

Step 2: Reassess After Optimization

If the patient remains symptomatic with persistent albuminuria and progressive CKD despite SGLT2 inhibitor therapy, finerenone could be considered for its renal protective effects, though this represents off-label use for HFrEF specifically.

If Finerenone Were Considered (Based on Extrapolation)

Eligibility Verification

• Confirm eGFR >25 mL/min/1.73 m² 4, 5
• Baseline potassium must be ≤5.0 mmol/L (FINEARTS-HF exclusion criterion) 6, ideally ≤4.8 mmol/L per your scenario
• Document symptomatic HF with objective evidence (not just biomarkers)
• Exclude HF mimickers (valvular disease, high-output states, constrictive pericarditis)

Dosing Strategy

Based on FINEARTS-HF protocol 4:

• If eGFR >60 mL/min/1.73 m²: Start 20 mg daily, titrate to 40 mg daily
• If eGFR ≤60 mL/min/1.73 m²: Start 10 mg daily, titrate to 20 mg daily

Monitoring Protocol

Critical monitoring windows 5, 7:

Week 4 after initiation or dose change:

• Serum potassium
• eGFR/creatinine
• Hold if K⁺ >5.5 mmol/L 7
• Reduce dose or discontinue if eGFR drops >25% from baseline 7

Ongoing:

• Reassess during acute illness, dehydration, or medication changes affecting potassium
• Monitor for symptomatic hypotension (occurred in 5.2% in real-world data) 7

Drug Interactions Requiring Dose Adjustment

• Strong CYP3A4 inhibitors (reduce finerenone dose by 50%)
• Moderate CYP3A4 inhibitors (avoid or use 10 mg daily maximum)
• Potassium-sparing diuretics, potassium supplements, NSAIDs increase hyperkalemia risk

Absolute Contraindications

• Serum potassium >5.0 mmol/L at baseline
• eGFR <25 mL/min/1.73 m²
• Addison's disease
• Concomitant strong CYP3A4 inhibitors (if dose adjustment not feasible)

Key Safety Considerations

Hyperkalemia risk is the primary concern, occurring in 10.4% of real-world patients 7. Risk is highest with 5:

• eGFR <60 mL/min/1.73 m²
• Baseline potassium >4.5 mmol/L
• Concomitant RAAS inhibitors

Patients with both low eGFR and elevated potassium had more frequent adverse events and treatment discontinuation (13.5% discontinued in real-world study) 5, 7, though relative risk reduction remained consistent across subgroups.

Renal function decline >25% occurred in 16.7% of patients, with >50% decline in 4.2% 7. This requires dose reduction or discontinuation.

Clinical Bottom Line

For your specific patient with HFrEF, T2DM, and CKD: Start or optimize an SGLT2 inhibitor immediately—this is the evidence-based priority with proven mortality benefit 1. Finerenone lacks specific outcome data in HFrEF populations and carries meaningful hyperkalemia risk that may complicate management of other proven HFrEF therapies. The guideline position reflects this evidence hierarchy, recommending against finerenone when superior alternatives exist 1.

If considering finerenone for renal protection after SGLT2 inhibitor optimization, ensure potassium ≤5.0 mmol/L, dose according to eGFR, and implement rigorous 4-week monitoring protocols to detect hyperkalemia and renal function decline early 5, 7.